![](https://investorshub.advfn.com/uicon/84756.png?cb=1487973117)
Monday, October 21, 2019 4:56:01 PM
GlobeNewswire•October 15, 2019
ALAMEDA, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a molecular diagnostics company providing actionable answers at critical decision points across the cancer care continuum, today announced the company will present data highlighting its proprietary liquid biopsy test, which has the potential to determine which nodules are benign to reduce the number of unnecessary biopsies and associated complications, during the CHEST Annual Meeting 2019. This year’s CHEST meeting is being held October 19-23, 2019 at the Ernest N. Morial Convention Center in New Orleans, LA.
Details of the poster discussion are as follows:
Poster #: E1101
Title: The Immune Response for Nodule Evaluation (IRENE) Cohort Profile
Presenter: Lyndal Hesterberg, Ph.D.
Date: Wednesday, October 23, 2019
Time: 10:15 a.m. – 10:20 a.m. CDT
About OncoCyte Corporation
OncoCyte is a molecular diagnostics company providing actionable answers at critical decision points across the lung cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The company is currently developing a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence, allowing them to be treated when their cancer is still responsive to adjuvant chemotherapy. DetermaVu, the company’s liquid biopsy test in development, utilizes a proprietary immune system interrogation approach to clarify which patients’ lung nodules are benign, enabling them to avoid potentially risky biopsy procedures.
OncoCyte Forward Looking Statements
Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are forward-looking statements. These statements include those pertaining to the time to complete and the results of OncoCyte’s ongoing CLIA Validation study of DetermaVu™, the closing of our planned acquisition of Razor and the Razor test, implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, the need and ability to obtain future capital, maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in OncoCyte’s Securities and Exchange Commission filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. OncoCyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contacts
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com
Media Contact
Andrew Mielach
LifeSci Public Relations, LLC
646-876-5868
amielach@lifescipublicrelations.com
'peace'
Recent OCX News
- Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move • GlobeNewswire Inc. • 06/24/2024 04:41:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:10:27 PM
- Oncocyte Appoints Andrea James as Chief Financial Officer • GlobeNewswire Inc. • 06/17/2024 08:05:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/04/2024 09:02:47 PM
- Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study • GlobeNewswire Inc. • 06/03/2024 06:13:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:05:31 PM
- Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine • GlobeNewswire Inc. • 05/30/2024 08:47:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:05:24 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/23/2024 03:26:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/23/2024 04:15:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 09:18:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 08:56:24 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/17/2024 09:11:17 PM
- Oncocyte Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/15/2024 08:05:00 PM
- Oncocyte to Announce First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/13/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/10/2024 09:31:11 PM
- PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace • GlobeNewswire Inc. • 05/07/2024 01:19:00 PM
- Oncocyte Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/12/2024 10:00:00 AM
- Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/12/2024 01:46:37 AM
- Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay • GlobeNewswire Inc. • 04/11/2024 09:30:00 PM
- Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 04/09/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:39:38 PM
- Oncocyte to Present at the Sequire Investor Summit in Puerto Rico • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays • GlobeNewswire Inc. • 12/06/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:19:59 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM